H 1227
An Act relative to patient access to biomarker testing to provide appropriate therapy
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To Governor
- Became Law
Bill overview
This bill aims to improve patient access to biomarker testing for cancer treatment. It seeks to ensure that patients have the opportunity to receive therapies tailored to their specific cancer type based on biomarker results. The legislation intends to remove barriers that may prevent patients from accessing these crucial tests. Ultimately, the goal is to improve cancer treatment outcomes by aligning therapies with individual patient characteristics.
Key provisions
- Expands access to biomarker testing for cancer patients.
- Requires insurance coverage for biomarker testing deemed medically necessary.
- Promotes collaboration between healthcare providers and laboratories to facilitate biomarker testing.
- Addresses potential barriers to biomarker testing, such as limited laboratory capacity.
- Encourages the use of standardized biomarker testing protocols.
- Supports research into the effectiveness of biomarker-driven therapies.
- Focuses on ensuring equitable access to biomarker testing across different populations.
- Requires reporting on the utilization of biomarker testing.
Who is affected
- Cancer patients
- Healthcare providers
- Insurance companies
- Laboratories performing biomarker testing
- The cancer care community
Notable changes
- The bill seeks to mandate insurance coverage for biomarker testing.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Meghan K. Kilcoyne
Cosponsors
Adrian C. Madaro
Adrianne Pusateri Ramos
Amy Mah Sangiolo
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.
Bill H.1227 194th (Current)
An Act relative to patient access to biomarker testing to provide appropriate therapy
By Representative Kilcoyne of Clinton, a petition (accompanied by bill, House, No. 1227) of Meghan K. Kilcoyne and others relative to cancer patient access to biomarker testing to provide appropriate therapy. Financial Services.
View Text Print Preview Download PDF
Bill Information
Bill Information
Presenter: Meghan K. Kilcoyne
Tabs
Bill History Petitioners Committee Summary Hearing Attendance
Bill History
Displaying 5 actions for Bill H.1227
| Date | Branch | Action |
| 2/27/2025 | House | Referred to the committee on Financial Services |
| 2/27/2025 | Senate | Senate concurred |
| 4/23/2025 | Joint | Hearing scheduled for 04/29/2025 from 10:00 AM-02:00 PM in A-2 |
| 7/31/2025 | House | Accompanied a new draft, see H4339 |
| 8/28/2025 | Joint | Hearing rescheduled to 04/29/2025 from 10:00 AM-01:00 PM in A-2 and Virtual Hearing updated to New End Time |
Similar Bills
H.4339 194th (Current)
An Act relative to patient access to biomarker testing to provide appropriate therapy
H.1074 193rd (2023 - 2024)
An Act relative to cancer patient access to biomarker testing to provide appropriate therapy
S.808 192nd (2021 - 2022)
An Act relative to cancer patient access to biomarker testing to provide appropriate therapy
S.809 194th (Current)
An Act relative to patient access to biomarker testing to provide appropriate therapy
S.689 193rd (2023 - 2024)
An Act relative to patient access to biomarker testing to provide appropriate therapy
The information contained in this website is for general information purposes only. The General Court provides this information as a public service and while we endeavor to keep the data accurate and current to the best of our ability, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.